跳至主要内容
临床试验/JPRN-jRCT1041190083
JPRN-jRCT1041190083招募中2 期

Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinib

Yamashita Tatsuya0 个研究点目标入组 33 人开始时间: 2019年11月21日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
33

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; AFP>=400ng/mL; good liver functional reserve; 20 years old or older, ECOG Performance status <=2; preservation of major organ function; written informed consent

排除标准

  • refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; unstable angina or myocardial infarction; severe complication; active infection; pregnant or lactating women and her partner, or women of childbearing potential; mental disorder; other factors unsuitable for participant

研究者

发起方
Yamashita Tatsuya

相似试验